Abeona Therapeutics (Nasdaq: ABEO) has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $155 million on June 27, 2025. The company's cash position, including PRV proceeds, reached approximately $225 million as of June 30, 2025.
The PRV was awarded by the FDA in April 2025 following the approval of ZEVASKYN™, the first FDA-approved autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa. The company expects to begin patient treatments with ZEVASKYN in Q3 2025 and projects profitability by early 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.